In last trading session, Cullinan Therapeutics Inc (NASDAQ:CGEM) saw 0.32 million shares changing hands with its beta currently measuring -0.16. Company’s recent per share price level of $9.03 trading at -$0.12 or -1.31% at ring of the bell on the day assigns it a market valuation of $525.79M. That closing price of CGEM’s stock is at a discount of -234.33% from its 52-week high price of $30.19 and is indicating a premium of 0.33% from its 52-week low price of $9.00.
For Cullinan Therapeutics Inc (CGEM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.74 in the current quarter.
Cullinan Therapeutics Inc (NASDAQ:CGEM) trade information
Upright in the red during last session for losing -1.31%, in the last five days CGEM remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $9.03 price level, adding 9.06% to its value on the day. Cullinan Therapeutics Inc’s shares saw a change of -25.86% in year-to-date performance and have moved -5.84% in past 5-day. Cullinan Therapeutics Inc (NASDAQ:CGEM) showed a performance of -14.08% in past 30-days.
Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 69.9% to its current value. Analysts have been projecting 30 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -232.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -232.23% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -62.42% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 18.99% while estimates for its earnings growth in next 5 years are of 7.34%.
Cullinan Therapeutics Inc (NASDAQ:CGEM)’s Major holders
BIOIMPACT CAPITAL LLC is the top institutional holder at CGEM for having 7.65 million shares of worth $133.39 million. And as of 2024-06-30, it was holding 13.8928 of the company’s outstanding shares.
The second largest institutional holder is BVF INC/IL, which was holding about 5.75 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.4459 of outstanding shares, having a total worth of $100.29 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.5 shares of worth $13.57 million or 2.58% of the total outstanding shares. The later fund manager was in possession of 1.45 shares on Nov 30, 2024 , making its stake of worth around $13.11 million in the company or a holder of 2.49% of company’s stock.
